ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Pharmacokinetics and CYP3A5 Pharmacogenetics for Once- Versus Twice-Daily Tacrolimus from First Dosing Day to 1 Year Post-Transplantation

S. Satoh, T. Niioka, H. Kagaya, K. Numakura, M. Saito, T. Inoue, N. Komine, S. Akihama, S. Narita, N. Tsuchiya, T. Habuchi, M. Miura

Division of Renal Replacement Therapeutic Science, Akita University School of Medicine, Akita, Japan
Pharmacy, Akita University Hospital, Akita, Japan
Urology, Akita University School of Medicine, Akita, Japan

Meeting: 2013 American Transplant Congress

Abstract number: B939

Related Abstracts
  • A Randomized Cross-Over Phase 3b Study of the Pharmacokinetics of Once-Daily Extended Release MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus in African-Americans (ASERTAA)
  • Comparison of Pharmacokinetics and Pharmacogenomics of Once-Daily Extended-Release MeltDose® Tacrolimus Tablets (Envarsus® XR) Vs. Twice-Daily Tacrolimus Capsules in Stable African American Kidney Transplant Patients: A Randomized Cross-Over Study

Backgrounds: Tacrolimus is available as an immediate-release, twice-daily formulation (Tac-BID), and a prolonged-release once-daily formulation (Tac-QD). A number of studies found that the daily dose was higher for Tac-QD than Tac-BID to achieve a similar trough level (C0). Patients with the CYP3A5*1 allele (CYP3A5 expressers) require a higher daily tacrolimus dose than those with the CYP3A5*3/*3 genotype (non-expressers) in order to maintain C0. The present study compares pharmacokinetics and CYP3A5 pharmacogenetics between Tac-BID and Tac-QD from the first dosing day (pre-transplantation) to 1-year post-transplantation, and its impact on clinical outcome.

Methods: The 24-h pharmacokinetics and CYP3A5 6986A>G pharmacogenetics were compared between Tac-QD and Tac-BID at pre-transplantation, and at 1-month and 1-year post-transplantation in 24 de novo renal transplant recipients in each formulation.

Results: The allele frequencies of CYP3A5*1 and 3 were 27.1% and 72.9% in each group. The dose-adjusted C0 and AUC0-24 of tacrolimus increased approximately two-fold from pre-transplantation to 1-year post-transplantation. Although there were good correlations between AUC0-24 and C0 for both formulations, the same C0 value achieved higher calculated AUC0-24 for Tac-QD than Tac-BID at all 3 time points. In patients with the CYP3A5*1 allele (CYP3A5 expressers), the dose-adjusted C0 and AUC0-24 were approximately 45% and 25%, respectively, lower for Tac-QD than Tac-BID at all 3 time points. In patients with the CYP3A5*3/*3 genotype (non-expressers), the dose-adjusted C0 was lower for Tac-QD than Tac-BID, but the difference in the dose-adjusted AUC0-24 was not significant. There were no remarkable differences in clinical outcomes between two formulations.

Conclusions: There are time dependent changes of pharmacokinetics and CYP3A5 pharmacogenetics in both formulations. Although its impact on clinical outcome may be minor, take notice that the target C0 achieving the same AUC0-24 may be different between Tac-QD and Tac-BID and between CYP3A5 expressers and non-expressers.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Satoh S, Niioka T, Kagaya H, Numakura K, Saito M, Inoue T, Komine N, Akihama S, Narita S, Tsuchiya N, Habuchi T, Miura M. Pharmacokinetics and CYP3A5 Pharmacogenetics for Once- Versus Twice-Daily Tacrolimus from First Dosing Day to 1 Year Post-Transplantation [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/pharmacokinetics-and-cyp3a5-pharmacogenetics-for-once-versus-twice-daily-tacrolimus-from-first-dosing-day-to-1-year-post-transplantation/. Accessed January 25, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.